113 related articles for article (PubMed ID: 17992293)
1. Functionalised cyclopentadienyl titanium compounds as potential anticancer drugs.
Allen OR; Gott AL; Hartley JA; Hartley JM; Knox RJ; McGowan PC
Dalton Trans; 2007 Nov; (43):5082-90. PubMed ID: 17992293
[TBL] [Abstract][Full Text] [Related]
2. Functionalised cyclopentadienyl zirconium compounds as potential anticancer drugs.
Allen OR; Knox RJ; McGowan PC
Dalton Trans; 2008 Oct; (39):5293-5. PubMed ID: 18827935
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, molecular structure and evaluation of new organometallic ruthenium anticancer agents.
Camm KD; El-Sokkary A; Gott AL; Stockley PG; Belyaeva T; McGowan PC
Dalton Trans; 2009 Dec; (48):10914-25. PubMed ID: 20023922
[TBL] [Abstract][Full Text] [Related]
4. Antitumour bis(cyclopentadienyl) metal complexes: titanocene and molybdocene dichloride and derivatives.
Abeysinghe PM; Harding MM
Dalton Trans; 2007 Aug; (32):3474-82. PubMed ID: 17680034
[TBL] [Abstract][Full Text] [Related]
5. Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride.
Tacke M; Cuffe LP; Gallagher WM; Lou Y; Mendoza O; Müller-Bunz H; Rehmann FJ; Sweeney N
J Inorg Biochem; 2004 Dec; 98(12):1987-94. PubMed ID: 15541486
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, characterization, cytotoxicity, and hydrolytic behavior of C2- and C1-symmetrical Ti(IV) complexes of tetradentate diamine bis(phenolato) ligands: a new class of antitumor agents.
Peri D; Meker S; Shavit M; Tshuva EY
Chemistry; 2009; 15(10):2403-15. PubMed ID: 19156656
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic studies of substituted titanocene and ansa-titanocene anticancer drugs.
Gómez-Ruiz S; Kaluderović GN; Prashar S; Polo-Cerón D; Fajardo M; Zizak Z; Sabo TJ; Juranić ZD
J Inorg Biochem; 2008 Aug; 102(8):1558-70. PubMed ID: 18353439
[TBL] [Abstract][Full Text] [Related]
8. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative activity of Titanocene Y against tumor colony-forming units.
Oberschmidt O; Hanauske AR; Pampillón C; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2007 Mar; 18(3):317-21. PubMed ID: 17264765
[TBL] [Abstract][Full Text] [Related]
10. Pseudo-halide derivatives of titanocene: synthesis and cytotoxicity studies.
Claffey J; Deally A; Gleeson B; Hogan M; Méndez LM; Müller-Bunz H; Patil S; Wallis D; Tacke M
Metallomics; 2009 Nov; 1(6):511-7. PubMed ID: 21305159
[TBL] [Abstract][Full Text] [Related]
11. Antitumor titanium compounds.
Caruso F; Rossi M
Mini Rev Med Chem; 2004 Jan; 4(1):49-60. PubMed ID: 14754443
[TBL] [Abstract][Full Text] [Related]
12. A comparative chemical-biological evaluation of titanium(IV) complexes with a salan or cyclopentadienyl ligand.
Schur J; Manna CM; Deally A; Köster RW; Tacke M; Tshuva EY; Ott I
Chem Commun (Camb); 2013 May; 49(42):4785-7. PubMed ID: 23598498
[TBL] [Abstract][Full Text] [Related]
13. Heteroaryl substituted titanocenes as potential anti-cancer drugs.
Sweeney N; Gallagher WM; Müller-Bunz H; Pampillón C; Strohfeldt K; Tacke M
J Inorg Biochem; 2006 Sep; 100(9):1479-86. PubMed ID: 16764931
[TBL] [Abstract][Full Text] [Related]
14. High antitumor activity of highly resistant salan-titanium(IV) complexes in nanoparticles: an identified active species.
Meker S; Margulis-Goshen K; Weiss E; Magdassi S; Tshuva EY
Angew Chem Int Ed Engl; 2012 Oct; 51(42):10515-7. PubMed ID: 22961758
[TBL] [Abstract][Full Text] [Related]
15. Phenanthroline derivatives with improved selectivity as DNA-targeting anticancer or antimicrobial drugs.
Roy S; Hagen KD; Maheswari PU; Lutz M; Spek AL; Reedijk J; van Wezel GP
ChemMedChem; 2008 Sep; 3(9):1427-34. PubMed ID: 18537202
[TBL] [Abstract][Full Text] [Related]
16. Titanium and vanadium complexes as anticancer agents.
Kostova I
Anticancer Agents Med Chem; 2009 Oct; 9(8):827-42. PubMed ID: 19538167
[TBL] [Abstract][Full Text] [Related]
17. A new generation of anticancer drugs: mesoporous materials modified with titanocene complexes.
Pérez-Quintanilla D; Gómez-Ruiz S; Zizak Z; Sierra I; Prashar S; del Hierro I; Fajardo M; Juranić ZD; Kaluderović GN
Chemistry; 2009; 15(22):5588-97. PubMed ID: 19370742
[TBL] [Abstract][Full Text] [Related]
18. Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands.
Marqués-Gallego P; Kalayda GV; Jaehde U; Dulk Hd; Brouwer J; Reedijk J
J Inorg Biochem; 2009 May; 103(5):791-6. PubMed ID: 19303143
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato) titanium(IV) compounds against Walker 256 carcinosarcoma. A new class of antineoplastic agents.
Keller HJ; Keppler B; Schmähl D
Arzneimittelforschung; 1982; 32(8):806-7. PubMed ID: 6890355
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines.
Kars MD; Işeri OD; Gunduz U; Molnar J
Chemotherapy; 2008; 54(3):194-200. PubMed ID: 18560226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
